BioNTech (NASDAQ:BNTX) Upgraded at TheStreet

TheStreet upgraded shares of BioNTech (NASDAQ:BNTX) from a c rating to a b- rating in a report published on Monday, TheStreetRatingsTable reports.

Several other analysts have also recently weighed in on BNTX. Jefferies Financial Group set a $230.00 price target on BioNTech in a report on Thursday, October 7th. Berenberg Bank set a $400.00 price target on BioNTech in a report on Tuesday, October 5th. Zacks Investment Research raised BioNTech from a hold rating to a buy rating and set a $272.00 target price on the stock in a research report on Tuesday. Redburn Partners reaffirmed a sell rating and set a $146.00 target price on shares of BioNTech in a research report on Wednesday, June 16th. They noted that the move was a valuation call. Finally, UBS Group set a $300.00 target price on BioNTech in a research report on Thursday, September 23rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of Hold and an average target price of $255.36.

Shares of BNTX stock opened at $249.40 on Monday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.57 and a current ratio of 2.67. The company has a market capitalization of $60.48 billion, a P/E ratio of 13.05 and a beta of -1.59. The company’s 50 day moving average price is $331.44 and its two-hundred day moving average price is $249.12. BioNTech has a 52 week low of $75.35 and a 52 week high of $464.00.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Sunday, August 8th. The company reported $10.77 EPS for the quarter, topping the Zacks’ consensus estimate of $8.35 by $2.42. BioNTech had a net margin of 52.48% and a return on equity of 159.73%. The firm had revenue of $5.31 billion during the quarter, compared to analysts’ expectations of $3.27 billion. During the same period in the previous year, the business posted ($0.38) earnings per share. The company’s revenue for the quarter was up 12599.8% compared to the same quarter last year. Analysts forecast that BioNTech will post 37.71 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the company. Primecap Management Co. CA grew its stake in shares of BioNTech by 4.2% during the 1st quarter. Primecap Management Co. CA now owns 4,821,718 shares of the company’s stock worth $526,483,000 after acquiring an additional 193,521 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of BioNTech by 31.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock worth $226,559,000 after acquiring an additional 500,085 shares during the period. FMR LLC grew its stake in shares of BioNTech by 13.8% during the 2nd quarter. FMR LLC now owns 1,997,013 shares of the company’s stock worth $447,092,000 after acquiring an additional 242,867 shares during the period. Fosun International Ltd bought a new position in shares of BioNTech during the 2nd quarter worth $353,904,000. Finally, BlackRock Inc. grew its stake in shares of BioNTech by 99.4% during the 2nd quarter. BlackRock Inc. now owns 1,481,390 shares of the company’s stock worth $331,654,000 after acquiring an additional 738,532 shares during the period. Institutional investors own 14.49% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.

See Also: What does a dividend yield signify to investors?

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.